The safety profile of CT-P13, a biosimilar candidate to Rituxan, also was comparable to the approved drug...Galapagos said the short-term efficacy and favorable safety profile supported the potential of JAK1 inhibition for RA treatment and confirmed results of its previous proof-of-concept study
Onconova has accumulated data from more than 850 patients with advanced, heavily pretreated solid tumors and hematological cancers in ongoing and completed trials of rigosertib, demonstrating a good safety profile for the drug
Onconova has accumulated data from more than 850 patients with advanced, heavily pretreated solid tumors and hematological cancers in ongoing and completed trials of rigosertib, demonstrating a good safety profile for the drug
By Marie Powers | BioWorld Today | Tuesday, June 18, 2013
safety profile consistent with previous studies 5/22/13 Baxter International Inc. (Deerfield, Ill.) Gamma-globulin Immunoglobulin Alzheimer's disease Phase III data showed it did not meet the co-primary endpoints of reducing cognitive decline and preserving functional abilities 5/8/13 Bayer Healthcare Pharmaceuticals Inc. (Berkeley, Calif.) and Onyx Pharmaceuticals Inc. (South San Francisco) Stivarga Regorafenib Metastatic gastrointestinal stromal tumor FDA approved it 5/16/13 Boehringer
The safety profile of CT-P13, a biosimilar candidate to Rituxan, also was comparable to the approved drug...Galapagos said the short-term efficacy and favorable safety profile supported the potential of JAK1 inhibition for RA treatment and confirmed results of its previous proof-of-concept study
Ablynx NV, of Ghent, Belgium, will make an oral and poster presentation for arthritis candidate, ALX-0061, at the Annual European Congress of Rheumatology in Madrid, Spain, showing a strong efficacy and safety profile for the drug in a Phase II study
DiaPep277 was well tolerated with a good safety profile, similar to that observed in DIA-AID 1, and no drug-related serious adverse events were reported
DiaPep277 was well tolerated with a good safety profile, similar to that observed in DIA-AID 1 , and no drug-related serious adverse events were reported
3SBio Inc., of Shenyang, China, said it completed its merger with Decade Sunshine Ltd., an exempted company with limited liability incorporated under the laws of the Cayman Islands. The firm also requested that trading of its American depositary shares on Nasdaq be suspended, while it works to delist its registered securities. Addex Therapeutics SA, of Geneva, completed a previously announced restructuring, and Bharatt Chowrir stepped down effectively immediately as CEO and as director of
No safety concerns relating to any of the aforementioned products have been identified in any preclinical and clinical data generated to date and there is no reason to believe that the favorable safety profile of the products will be affected
AbbVie Inc., of Chicago, reported results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and relapsed/refractory non-Hodgkin's lymphoma (NHL). The Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in
AstraZeneca plc, of London, said results from two pivotal Phase III studies of naloxegol showed that the 25-mg dose met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies
The fusion molecule directs a targeted interferon alpha mediated cytotoxic effect on lymphoma cells leading to dramatically improved efficacy and safety profiles in preclinical studies
Taken together, the three studies demonstrated that AE37 is meeting or exceeding all expectations for generating a specific, robust and long-lived immune response while maintaining a favorable safety profile, the company said
The safety profile, considered by itself, suggested approval for the drug was merited, the committee decided by an 8-5 ballot, but that was not sufficient to save Ampligen
By Randy Osborne | BioWorld Today | Wednesday, May 22, 2013
AstraZeneca plc, of London, said results from two pivotal Phase III studies of naloxegol showed that the 25-mg dose met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies
The study showed a good safety profile, with no drug-related serious adverse events to date